

# Genomic ventures to explore tumour development and intra-tumour heterogeneity in breast cancer

Peter Van Loo


Francis Crick Institute, London, UK  
and Department of Human Genetics,  
University of Leuven, Belgium



# Disclosure information


- I have no financial relationships or potential conflicts of interest to disclose

# The cancer genome




Source: SKY Karyotypes and FISH analysis of Epithelial Cancer Cell Lines,  
Cancer Genomics Program, Department of Pathology and Oncology, University of Cambridge,  
<http://www.path.cam.ac.uk/~pawefish/index.html>


# Evolution of the cancer genome



# Tumour evolution and intra-tumour heterogeneity



Yates and Campbell (2012), *Nat Rev Genet* 13:795-806




Navin *et al.* (2010). *Genome Res* 20:68-80




The background is a faded image of a manuscript page. It features handwritten Greek text in a cursive script, with some words in red ink (rubrication). A prominent diagram shows a hand holding a staff or scepter, possibly a symbol of authority or a medical instrument. The overall tone is historical and scholarly.

**What can a  
cancer genome tell us  
about its past?**

# Evolution of cancer genomes in time





# Evolution of cancer genomes in time






# Timing copy number gains




# A breast cancer genome sequenced to 188X coverage



Estimated purity: 70% tumor cells, 30% normal cells


Van Loo\*, Nordgard\* *et al.* (2010),  
Allele-specific copy number analysis  
of tumors. *PNAS* 107:16910-16915.

# Detecting subclonal copy number changes








# Point mutations



# Subclones in mutation data modeled with a Bayesian Dirichlet process



# Phylogenetic tree







# The pigeonhole principle




# Phylogenetic tree






# Phylogenetic tree



# What fraction of breast cancers show subclonal mutations?




# Studying (sub)clonal evolution across samples






# Sequencing single breast cancer cells





- 4 subclones HCC38 (millions of cells)
- 4 single cells PCR-based amplification
- 4 single cells MDA-based amplification





Voet *et al.* (2013), Single-cell paired-end genome sequencing reveals structural variation per cell cycle. *Nucleic Acids Research* 41:6119-6138.



# Sister cells show complementary aberrations







# Single cell and bulk tumour sequencing of a primary breast cancer




**Breast tumor**  
3 regions  
189 cells


**Adjacent normal**  
(6 cells)



# Single cell and bulk tumour sequencing of a primary breast cancer




# Sequencing disseminated tumour cells




98.6 %  
concordance

Ploidy: 1.96, aberrant cell fraction: 73%, goodness of fit: 99.0%




# Sequencing disseminated tumour cells




89.4 %  
concordance

Ploidy: 1.90, aberrant cell fraction: 54%, goodness of fit: 99.2%






# Sequencing disseminated tumour cells




Ploidy: 1.90, aberrant cell fraction: 54%, goodness of fit: 99.2%







# Sequencing disseminated tumour cells




Ploidy: 1.90, aberrant cell fraction: 54%, goodness of fit: 99.2%



# Sequencing disseminated tumour cells




Ploidy: 1.90, aberrant cell fraction: 54%, goodness of fit: 99.2%




# Phylogeny inference

MRCA  
primary  
tumour




+1q, +13, +16p




Subclones  
primary  
tumour

+20







+21



DTC

# Similarities and differences between DTCs



# Conclusions

- **Molecular archeology of cancer:**
  - **Disentangle the subclonal architecture and life history of tumours** from one cancer sample
  - **Track evolution** of clones and subclones over time and space
- **Single cell sequencing:**
  - Obtain **accurate copy number profiles**
  - **Infer phylogeny** of single tumour cells and DTCs
  - Allows to see **changes over one cell cycle**



# Thank you!

**Cancer Genome Project,  
Wellcome Trust Sanger Institute**

*Peter Campbell*

Mike Stratton

Andy Futreal

***David Wedge***

*Serena Nik-Zainal*

Lucy Yates

Gunes Gundem

Helen Davies

And many others!

The Breast Cancer Working Group  
of the International Cancer Genome  
Consortium

**Department of Human Genetics,  
University of Leuven, Belgium**

***Thierry Voet***

*Parveen Kumar*

**Department of Genetics, Institute  
for Cancer Research, Oslo, Norway**

*Elen Møller*

Silje Nord

Ole Christian Lingjærde

Anne-Lise Børresen-Dale

Vessela Kristensen

**Department of Human Genetics,  
University of Chicago, USA**

Kevin White

**Department of Pathology, Institut  
Jules Bordet, Brussels, Belgium**

Christine Desmedt

Christos Sotiriou



# Genomic ventures to explore tumour development and intra-tumour heterogeneity in breast cancer

**We are recruiting!**

Peter Van Loo

Francis Crick Institute, London, UK  
and Department of Human Genetics,  
University of Leuven, Belgium

**[Peter.VanLoo@crick.ac.uk](mailto:Peter.VanLoo@crick.ac.uk)**

THE  
FRANCIS  
CRICK  
INSTITUTE



International  
Cancer Genome  
Consortium